74Figure: Collaboration between IMS and DMP for the development of innovative new biologics, pharma-ceuticals and medical technologiesmaceuticals and medical technologies by facilitating the transfer of basic research discoveries within the institute. DMP was founded in RIKEN in 2010 in order to support all phases of development of new therapeutics, from the discovery of promis-ing targets to the identification of potential lead compounds, such as small molecules and antibodies, and the acquisition of intel-lectual property rights to drugs and technologies that can then be brought to the development phase.To achieve effective progress in this area, DMP established nine Drug Discovery Basic Units, in which the types of studies being performed are organized according to the expertise of each PI. IMS contributes to this effort in several ways, including by set-ting up a facility for the development of antibody drugs, the Drug Discovery Antibody Platform Unit. In 2021, IMS now has six collaborative programs with DMP: Artificial adjuvant vector cells (Shin-ichiro Fujii), Cancer therapy with iPS-derived NKT cells (Haruhiko Koseki), Drugs for allergic diseases (Masato Kubo), Neutralizing mAb for HBV infection (Daiki Miki) and Thera-peutic mAb for IBD (Takashi Saito). The investigator-initiated Phase I clinical trial of the Artificial adjuvant vector cell project for cancer therapy has been completed and the Phase II study was then started. In addition, another phase I study, an iPS-NKT cell clinical trial for head and neck cancer, has started.Linkage to RIKEN Program for Drug Discovery and Medical Technology Platforms (DMP)IMS collaborates with DMP to develop innovative new phar-
元のページ ../index.html#80